Monday, August 15, 2022
    HomeHealthPharmalittle: Sarepta halts a Duchenne clinical trial over safety;

    Pharmalittle: Sarepta halts a Duchenne clinical trial over safety;


    And so, one other working week will quickly draw to a detailed. Not a second too quickly, sure? That is, it’s possible you’ll recall, our treasured sign to daydream about weekend plans. Our agenda continues to be coming collectively. For the second, we anticipate to walk about with the official mascot and manicure the Pharmalot grounds. In any other case, we hope to hold with Mrs. Pharmalot and have a listening social gathering. And what about you? It is a positive time to benefit from the nice outside. You can keep indoors and stream a shifting image. Trying forward, you may make a summer season getaway plan or refill on sundry gadgets earlier than costs rise once more subsequent week. Effectively, no matter you do, have a grand time. However be protected. Get pleasure from, and see you quickly…

    Sarepta Therapeutics has briefly stopped a scientific trial of its second-generation medication for sufferers with a sure kind of Duchenne muscular dystrophy on account of a severe security incident reported by a affected person, STAT reviews. The U.S. Meals and Drug Administration positioned a scientific maintain on the Sarepta drug, known as SRP-5051, after a affected person within the examine skilled a “severe” lower in blood-based magnesium, a situation often called hypomagnesemia. SRP-5051 belongs to a brand new class of remedies, which Sarepta refers to as its “PPMO platform,” that has develop into extra essential for the corporate following important setbacks with its efforts to develop a one-time gene remedy for Duchenne.

    Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!


    Source link

    Related articles

    Stay Connected


    Latest posts